DEPARTMENT OF HEALTH SERVICES
Division of Medicaid Services
F-01952 (01/2025)

STATE OF WISCONSIN
Wis. Admin. Code § DHS 107.10(2)

FORWARDHEALTH

PRIOR AUTHORIZATION DRUG ATTACHMENT FOR CYTOKINE AND CELL ADHESION MOLECULE (CAM) ANTAGONIST DRUGS FOR GIANT CELL ARTERITIS AND NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA)

INSTRUCTIONS: Type or print clearly. Before completing this form, read the Prior Authorization Drug Attachment for Cytokine and Cell Adhesion Molecule (CAM) Antagonist Drugs for Giant Cell Arteritis and Non-Radiographic Axial Spondyloarthritis (nr-axSpA) Instructions, F-01952A. Prescribers may refer to the Forms page of the ForwardHealth Portal at forwardhealth.wi.gov/WIPortal/Subsystem/Publications/ForwardHealthCommunications.aspx?panel=Forms for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization Drug Attachment for Cytokine and CAM Antagonist Drugs for Giant Cell Arteritis and nr-axSpA form signed and dated by the prescriber before submitting a PA request on the Portal, by fax, or by mail. Prescribers and pharmacy providers may call Provider Services at 800-947-9627 with questions.

SECTION I – MEMBER INFORMATION

1. Name – Member (Last, First, Middle Initial)

2. Member ID Number	3. Date of Birth – Member

SECTION II – PRESCRIPTION INFORMATION

4. Drug Name	5. Drug Strength
6. Date Prescription Written	7. Directions for Use

8. Name – Prescriber

9. Address – Prescriber (Street, City, State, Zip+4 Code)

10. Phone Number – Prescriber	11. National Provider Identifier – Prescriber

SECTION III – CLINICAL INFORMATION (Required for All PA Requests)

12. Diagnosis Code and Description

Note: Supporting clinical information and a copy of the member's current medical records must be submitted with all PA requests.

DT-PA120-120

SECTION III A – CLINICAL INFORMATION FOR GIANT CELL ARTERITIS ONLY

13. Does the member have giant cell arteritis? ❑ Yes ❑ No

14. Is the prescription written by a rheumatologist or through a rheumatology consultation? ❑ Yes ❑ No

15. Is the member currently using the requested non-preferred drug? ❑ Yes ❑ No

    If yes, indicate the approximate date therapy was started.

16. Has the member taken Tyenne subQ for **at least three** consecutive months and experienced an unsatisfactory therapeutic response or a clinically significant adverse drug reaction? ❑ Yes ❑ No

    If yes, list the Tyenne subQ dose and dates taken and describe the unsatisfactory therapeutic response or clinically significant adverse drug reaction. If additional space is needed, continue documentation in Section V of this form.

    Dose: _____ Dates Taken: _____

    Describe the unsatisfactory therapeutic response or clinically significant adverse drug reaction.

17. Indicate the clinical reason(s) why the prescriber is requesting a non-preferred cytokine and CAM antagonist drug.

SECTION III B – CLINICAL INFORMATION FOR NR-AXSPA ONLY

18. Does the member have nr-axSpA? ❑ Yes ❑ No

19. Is the prescription written by a rheumatologist or through a rheumatology consultation? ❑ Yes ❑ No

20. Is the member currently using the requested non-preferred drug? ❑ Yes ❑ No

    If yes, indicate the approximate date therapy was started.

21. Has the member taken Cimzia for **at least three** consecutive months and experienced an unsatisfactory therapeutic response or a clinically significant adverse drug reaction? ❑ Yes ❑ No

    If yes, list the Cimzia dose and dates taken and describe the unsatisfactory therapeutic response or clinically significant adverse drug reaction. If additional space is needed, continue documentation in Section V of this form.

    Dose: _____ Dates Taken: _____

    Describe the unsatisfactory therapeutic response or clinically significant adverse drug reaction.

22. Indicate the clinical reason(s) why the prescriber is requesting a non-preferred cytokine and CAM antagonist drug.

SECTION IV – AUTHORIZED SIGNATURE

23. **SIGNATURE** – Prescriber	24. Date Signed

SECTION V – ADDITIONAL INFORMATION

25. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the drug requested may be included here.

Reset Form